Significance of KRAS Gene Mutations in Colorectal Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 25 January 2025 | Viewed by 3987
Special Issue Editors
Interests: cancer genetics; translational medicine; molecular diagnostics
Interests: molecular profile of gastrointestinal stromal tumors (GIST); clinical cancer genomic profiling; translational medicine; molecular genetics; cancer; solid tumor; molecular biomarkers; NGS technologies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Understanding biological and genetic factors is critical for therapeutic strategies and improved survival outcomes.
One of these critical steps is understanding the mechanism and development of treatment targets for metastatic colorectal cancers with the KRAS mutation.
Notably, KRAS mutations occur in many cancers with different mutation frequencies, but there is also considerable variation in mutation subtypes.
Nonetheless, the future of KRAS-directed therapy is promising.
The data require increasingly more effort to seek a better understanding to overcome what has been an un-druggable target in oncology for a long time.
The purpose of this Special Issue is to present advances regarding the heterogeneity of KRAS mutant tumors and multiple subtypes of KRAS mutant forms. Precise selection of patients for cancer-directed therapy will be necessary to ensure its efficacy.
This Special Issue welcomes reviews, as well as original research articles, which should be submitted by the deadline of 25 January 2024.
Prof. Dr. Grazia Palomba
Dr. Maria Cristina Sini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- KRAS
- colorectal cancer
- target therapy
- mechanism
- treatment targets
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
